Communiqués NKGen Biotech, Inc.

Actions

NKGN

US65488A1016

Cours en clôture Nasdaq Autres places de cotation 00:00:00 05/06/2024			Varia. 5j.	Varia. 1 janv.
1,45 ^USD	+0,69%		-7,64%	-47,27%

03/06	NKGen Biotech, Inc. présentera des données de phase 1 actualisées sur la thérapie cellulaire NK allogénique SNK02 dans les tumeurs solides lors du 6e sommet annuel sur les thérapies cellulaires allogéniques (6e Annual Allogeneic Cell Therapies Summit 2024)	CI
23/05	NKGen Biotech publie les résultats de l'analyse intermédiaire de la phase 1 de la thérapie par cellules NK allogéniques SNK02 dans les tumeurs solides avancées lors de la réunion annuelle de l'American Society of Clinical Oncology (ASCO) en 2024.	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024	03/06	AQ
Spotlighting Unexplored Stocks in Focus: NKGN, INBS, BTBT, PRSO, MGOL	24/05	AQ
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	23/05	AQ
NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease	20/05	AQ
NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition	16/05	AQ
NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease	29/04	AQ
NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit	25/04	AQ
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology Annual Meeting	25/04	AQ
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24/04	AQ
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's and Parkinson's Drug Development Summit	19/04	AQ
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit	18/04	AQ
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs	11/04	AQ
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's disease at the Tau2024 Global Conference	26/03	AQ
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference	25/03	AQ
NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease at the Tau2024 Global Conference	04/03	AQ
Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies	07/02	AQ
NKGen Biotech Advances Alzheimer's Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial	29/12	AQ
NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer’s Disease	28/12	AQ
NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer's Disease	28/12	AQ
NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease	27/12	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués NKGen Biotech, Inc.

Actions

NKGN

US65488A1016

Communiqués

Filtres